clinical trial · NCT06816108
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Ono Pharmaceutical Co., Ltd.·phase1·recruiting·n = 60
Solid TumorNSCLCONO-7428
brief summary
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
started
Apr 21, 2025
primary completion
Jul 1, 2029
completion
Jul 1, 2029
last updated
Jan 12, 2026
official title
A Phase I, Open-label, Dose Escalation Study to Evaluate the Tolerability and Safety of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol